image 2 image 4
Skip Navigation Links
 Home 
 Congress Structure 
 Important Dates 
 Venue 
 Registration 
 Pre Registered 
 Hotel Info 
 Abstracts 
 Scientific Program 
 Social Program 
 Exhibition 
 Contact Us 
       XXV Annual Congress of the Iranian Society of Ophthalmology        بـیــست و پنجمین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران
مقاله Abstract


Title: Visual and anatomical outcomes of spironolactone therapy in chronic central serous chorioretinopathy
Author(s): Khalil Ghasemi Falavarjani, Anahita Amirsardari, Abbas Habibi, Acieh Eshaghi, Kaveh Abri Aghdam
Presentation Type: Oral
Subject: Posterior Segment and Uveitis
Others:
Presenting Author:
Name: Kaveh Abri aghdam
Affiliation :(optional) Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
E mail: kaveh_abri@yahoo.com
Phone: 0098-21-66509162
Mobile:
Purpose:

To evaluate the effects of spironolactone on chronic central serous chorioretinopathy (CSC).

Methods:

This is a prospective interventional case series on sixteen eyes of 14 patients with chronic CSC. Patients were treated with spironolactone 25 mg daily for at least 6 weeks. If there was an incomplete resolution of subretinal fluid (SRF), the treatment was continued with increasing the dosage to 25 mg twice daily. Primary outcome measures were the changes in maximum SRF height and central macular thickness (CMT) at 6 weeks and at the final follow-up visit as recorded by OCT. Secondary outcome measure was the change in BCVA.

Results:

Mean follow-up time was 6.4 ± 4.3 months. Baseline BCVA was 0.54 ± 0.44 LogMAR and improved to 0.42 ± 0.43 LogMAR at the final visit (P=0.04). Mean CMT decreased from 282.69 ± 103.23 µm at baseline to 236.75 ± 90.10 µm at final visit (p= 0.11). Mean maximum height of SRF reduced from 155.63 ± 95.27 µm at baseline to 77.19 ± 95.68 µm at the final visit (P=0.04). SRF resolved completely in 7 eyes (43.75%).

Conclusion:

In eyes with persistent SRF due to CSC, spironolactone therapy was associated with a significant reduction in maximum SRF height and BCVA improvement.

Attachment:





Skip Navigation Links
        صفحه اصلی
        ساختار کنگره
        تاریخ های مهم
        مکان برگزاری
        ثبت نام
        ثبت نام شدگان
        اطلاعات هتل - رزرو
        مقالات
        برنامه کنگره
        جشنواره فیلم و عکس
        نمایشگاه
        تماس با ما
        جستجوی سخنران
 
Last News

  - بـیــست و پنجمین کنــگــره سـالیـانه انـجـمـن چـشـم پـزشـکی ایـــران